PRIMARY MALIGNANT MELANOMA UTERINE CERVIX
Abstract
A 40-year-old premenopausal female presented with foul-smelling per vaginal discharge for 3 months. Diagnostic work revealed a locally advanced primary malignant melanoma of uterine cervix. The patient declined pelvic surgery and was treated with Dacarbazine. Malignant melanoma is a rare tumour of skin and has been ranked in the top ve cancers of Australia and Sweden. It is a tumour of melanocytes which forms melanin pigment in the skin. In men, the most common site is trunk while in females common site is limbs. However, melanoma can arise from mucosal surfaces where the melanocytes are present. Most common mucosal sites are head and neck followed by female genital tract.
Key words: Cervix, dacarbazine, malignant melanoma
References
Saika K, Sobue T. Cancer statistics in the world. Gan To Kagaku Ryoho 2013;40:2475-80.
Baxter AJ, Hughes MC, Kvaskoff M, et al. The Queensland study of melanoma: Environmental and genetic associations (Q-MEGA); study design, baseline characteristics, and repeatability of phenotype and sun exposure measures. Twin Res Hum Genet 2008;11:183-96.
Ahmed A, Alam MB, Khan W, et al. Frequency and characteristics of skin cancers diagnosed at Ayub medical college, Abbottabad Pakistan from 1995-2003. J Ayub Med Coll Abbottabad 2007;19:3 6.
Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. The American college of surgeons commission on cancer and the American cancer society. Cancer 1998;83:1664-78.
Calderón-Salazar L, de Leon DC, Montiel DP, et al. Primary malignant melanoma of the uterine cervix treated with ultraradical surgery: A case report. ISRN Obstet Gynecol 2011;2011:683020.
Simões M, Cunha V, Nabais H, et al. Primary malignant melanoma of the uterine cervix--case report and review. Eur J Gynaecol Oncol 2011;32:448-51.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.
